From a study out of US and
Mexican university psychiatric
departments comes a novel
treatment for social anxiety in the
form of a nasal spray.
The authors conducted a phase II,
multicenter, randomized, doubleblind,
placebo-controlled study
using a single-dose of PH94B.
Ninety-one women aged from 19
to 60 years of age with generalised
social anxiety disorder were
involved, with the study recording
a significantly greater decrease in
mean Subjective Units of Distress
scores.
The authors concluded that
PH94B may be an effective, and
well-tolerated acute treatment for
performance and social anxiety in
women with social anxiety disorder.
CLICK HERE to access the study.The above article was sent to subscribers in Pharmacy Daily's issue from 22 Apr 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Apr 14
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.